Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–59.

PubMed  Google Scholar 

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissues. 2017. https://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017.

Rimsza LM, Li H, Braziel RM, Spier CM, Persky DO, Dunlap J, et al. Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica. 2018;103:e151–e153.

CAS  PubMed  PubMed Central  Google Scholar 

Kroft SH. Stratification of follicular lymphoma: time for a paradigm shift? Am J Clin Pathol. 2019;151:539–41.

PubMed  Google Scholar 

Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, et al. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol. 2016;27:1323–9.

CAS  PubMed  Google Scholar 

Mustafa Ali M, Rybicki L, Nomani L, Rouphail B, Dean RM, Hill BT, et al. Grade 3 follicular lymphoma: outcomes in the rituximab era. Clin Lymphoma Myeloma Leuk. 2017;17:797–803.

PubMed  Google Scholar 

Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, et al. Multicenter analysis of advanced stage grade 3A follicular lymphoma outcomes by frontline treatment regimen. Clin Lymphoma Myeloma Leuk. 2019;19:95–102.

PubMed  Google Scholar 

Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229–53.

CAS  PubMed  PubMed Central  Google Scholar 

Barraclough A, Bishton M, Cheah CY, Villa D, Hawkes EA. The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma. Br J Haematol. 2021;195:15–24.

CAS  PubMed  Google Scholar 

Koch K, Richter J, Hänel C, Hüttmann A, Dührsen U, Klapper W. Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/transformation. Haematologica. 2022;107:2144–53.

CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Link BK, Witzig TE, Maurer MJ, Allmer C, King RL, et al. Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood. 2019;134:1289–97.

CAS  PubMed  PubMed Central  Google Scholar 

Magnano L, Balagué O, Dlouhy I, Rovira J, Karube K, Pinyol M, et al. Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma. Ann Oncol. 2017;28:2799–805.

CAS  PubMed  Google Scholar 

Horn H, Schmelter C, Leich E, Salaverria I, Katzenberger T, Ott MM, et al. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica. 2011;96:1327–34.

PubMed  PubMed Central  Google Scholar 

Bosga-Bouwer AG, van Imhoff GW, Boonstra R, van der Veen A, Haralambieva E, van den Berg A, et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood. 2003;101:1149–54.

CAS  PubMed  Google Scholar 

Ott G, Katzenberger T, Lohr A, Kindelberger S, Rüdiger T, Wilhelm M, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood. 2002;99:3806–12.

CAS  PubMed  Google Scholar 

Katzenberger T, Ott G, Klein T, Kalla J, Müller-Hermelink HK, Ott MM. Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. Am J Pathol. 2004;165:481–90.

CAS  PubMed  PubMed Central  Google Scholar 

Yuan J, Greiner TC, Fu K, Smith LM, Aoun P, Chan WC, et al. Rituximab improves the outcome of patients with grade 3 follicular lymphoma receiving anthracycline-based therapy. Clin Lymphoma Myeloma Leuk. 2017;17:488–97.e2.

PubMed  Google Scholar 

Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB, et al. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol. 2012;156:225–33.

PubMed  Google Scholar 

Barraclough A, England JT, Villa D, Wight J, Hapgood G, Conn J, et al. Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance. Haematologica. 2023;108:2444–53.

PubMed  PubMed Central  Google Scholar 

Hans CP, Weisenburger DD, Vose JM, Hock LM, Lynch JC, Aoun P, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood. 2003;101:2363–7.

CAS  PubMed  Google Scholar 

Ganti AK, Weisenburger DD, Smith LM, Hans CP, Bociek RG, Bierman PJ, et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol. 2006;17:920–7.

CAS  PubMed  Google Scholar 

Cerhan JR, Link BK, Habermann TM, Maurer MJ, Feldman AL, Syrbu SI, et al. Cohort profile: the lymphoma specialized program of research excellence (SPORE) molecular epidemiology resource (MER) cohort study. Int J Epidemiol. 2017;46:1753–54i.

PubMed  PubMed Central  Google Scholar 

Cerhan JR, Maurer MJ, Link BK, Feldman AL, Habermann TM, Jaye DL, et al. The lymphoma epidemiology of outcomes cohort study: design, baseline characteristics, and early outcomes. Am J Hematol. 2024;99:408–21.

CAS  PubMed  PubMed Central  Google Scholar 

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

CAS  PubMed  PubMed Central  Google Scholar 

Wenzl K, Stokes ME, Novak JP, Bock AM, Khan S, Hopper MA, et al. Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL. Blood Cancer J. 2024;14:100.

PubMed  PubMed Central  Google Scholar 

Alduaij W, Collinge B, Ben-Neriah S, Jiang A, Hilton LK, Boyle M, et al. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population. Blood. 2023;141:2493–507.

CAS  PubMed  Google Scholar 

Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91:1096–101.

PubMed  PubMed Central  Google Scholar 

Mondello P, Fama A, Larson MC, Feldman AL, Villasboas JC, Yang ZZ, et al. Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer J. 2021;11:130.

PubMed  PubMed Central  Google Scholar 

Shustik J, Quinn M, Connors JM, Gascoyne RD, Skinnider B, Sehn LH. Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol. 2011;22:1164–9.

CAS  PubMed  Google Scholar 

Nowak MA, Sigmund K. Evolutionary dynamics of biological games. Science. 2004;303:793–9.

CAS  PubMed  Google Scholar 

Bobée V, Viennot M, Rainville V, Veresezan L, Drieux F, Viailly PJ, et al. Analysis of immunoglobulin/T-cell receptor repertoires by high-throughput RNA sequencing reveals a continuous dynamic of positive clonal selection in follicular lymphoma. Hemasphere. 2024;8:e50.

PubMed  PubMed Central  Google Scholar 

Sarkozy C, Wu S, Takata K, Aoki T, Ben-Neriah S, Milne K, et al. Integrated single cell analysis reveals co-evolution of malignant B cells and the tumor microenvironment in transformed follicular lymphoma. Cancer Cell. 2024;42:1003–17.e6.

CAS  PubMed  Google Scholar 

Siegmund KD, Marjoram P, Woo YJ, Tavaré S, Shibata D. Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers. Proc Natl Acad Sci USA. 2009;106:4828–33.

Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472:90–4.

CAS  PubMed  PubMed Central  Google Scholar 

Mondello P, Ansell SM, Nowakowski GS. Immune epigenetic crosstalk between malignant B cells and the tumor microenvironment in B cell lymphoma. Front Genet. 2022;13:826594.

CAS  PubMed  PubMed Central  Google Scholar 

Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516–22.

CAS  PubMed  PubMed Central  Google Scholar 

Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128:1112–20.